Loading stock data…
Nutriband Inc. (NTRB)
$3.21+0.15 (+4.90%)
After Hours$3.21+0.00 (+0.00%)· Last close Jun 29
Nutriband Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nutriband Inc. in the Healthcare sector is trading at $3.21 with a market capitalization of $43M. Wall Street consensus targets $15.00 (1 analysts), implying a +367.3% move over the next 12 months. The stock is currently near its 52-week low of $2.90, remaining 33.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +367.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $400,709↑ | $346,058↓ | $622,452↓ | $667,432↑ | $642,379 |
| Gross Profit | $88,941↑ | $68,505↓ | $156,881↓ | $251,981↓ | $285,944 |
| Operating Income | -$1.02M↑ | -$3.88M↓ | -$2.00M↓ | -$1.41M↑ | -$1.96M |
| Net Income | -$968,059↑ | -$3.87M↓ | -$2.00M↓ | -$1.39M↑ | -$5.52M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$42.67M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-123.21%
Volume
Today's trading volume
15,944
Recent News
The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
Nutriband (NTRB) announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter read, in part, “As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the begin
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of +26.44% and -27.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?